A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors

被引：10

作者：

Naing, Aung

Gelderblom, Hans

Gainor, Justin F.

Forde, Patrick M.

Butler, Marcus

Lin, Chia-Chi

Sharma, Sunil

de Olza, Maria Ochoa

Schellens, Jan H. M.

Soria, Jean-Charles

Taylor, Matthew H.

Silva, Antonio P.

Li, Zhonggai

Bilic, Sanela

Cameron, Scott

Infante, Jeffrey R.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut Phase Program 1, Houston, TX USA

[2] Leiden Univ, Med Ctr, Leiden, Netherlands

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] Huntsman Canc Inst, Salt Lake City, UT USA

[8] Vall Hebron Univ Hosp, Barcelona, Spain

[9] Netherlands Canc Inst, Amsterdam, Netherlands

[10] Inst Gustave Roussy, Villejuif, France

[11] Oregon Hlth & Sci Univ, Portland, OR USA

[12] Novartis Pharma AG, Basel, Switzerland

[13] Novartis Inst BioMed Res, Cambridge, MA USA

[14] Sarah Cannon Res Inst, Nashville, TN USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.3060

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3060

引用

页数：2